Skip to main content
UCB logo

UCB — Investor Relations & Filings

Ticker · UCB ISIN · BE0003739530 LEI · 2138008J191VLSGY5A09 BR Manufacturing
Open in API
Filings indexed 2,023 across all filing types
Latest filing 2018-03-23 AGM Information
Country BE Belgium
Listing BR UCB

About UCB

https://www.ucb.com/

UCB is a global biopharmaceutical company that focuses on creating solutions for people living with severe diseases, primarily in the fields of neurology and immunology. The company's core activities include the research, development, and commercialization of pharmaceutical and biotechnology products. Guided by a patient-centric and science-driven approach, UCB is committed to innovation and sustainability. Through its UCB Ventures arm, it invests in pioneering technologies and companies with the potential to transform patient care. The company also offers personalized support services to patients and healthcare professionals during their treatment journey with a UCB medicine.

Recent filings

Filing Released Lang Actions
Oproeping AGM 26 april 2018.pdf
AGM Information Classification · 98% confidence The document is explicitly titled "OPROEPING TOT DE ALGEMENE VERGADERING VAN AANDEELHOUDERS" (Notice of the General Meeting of Shareholders) and details the agenda items for a meeting scheduled for April 26, 2018. The agenda includes voting on the annual accounts, approval of the remuneration report, reappointment of directors and the auditor, and specific corporate actions related to incentive plans and financing agreements (Change of Control clauses). This content is characteristic of materials distributed to shareholders in advance of an Annual General Meeting (AGM) to inform their voting decisions. While it touches upon remuneration (DEF 14A topics) and annual results (10-K topics), the primary purpose and format are that of a formal notice and agenda for the AGM. Therefore, the most appropriate classification is AGM Information (AGM-R).
2018-03-23 Dutch
UCB SA-NV Proxy General Meeting 26 April 2018.pdf
Proxy Solicitation & Information Statement Classification · 99% confidence The document is explicitly titled "PROXY FOR THE GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON 26 APRIL 2018". It contains instructions on how to appoint a proxy holder, voting instructions for various resolutions (including approval of annual accounts, remuneration report, director renewals, and capital authorization), and details about both Ordinary and Extraordinary General Meetings. This content is characteristic of materials sent to shareholders to solicit their votes and appoint representatives for a shareholder meeting, which falls under the definition of Proxy Solicitation & Information Statement.
2018-03-23 English
2017 annual report (final).pdf
Annual Report Classification · 100% confidence The document is explicitly titled 'Annual Report 2017' and contains a comprehensive overview of the company's performance, including a letter to stakeholders, strategy, management report, consolidated financial statements, and auditor's report. It is a full-length annual report, not an announcement or a summary. FY 2017
2018-03-23 English
1803 - Bio Cédric van Rijckevorsel.pdf
Board/Management Information Classification · 99% confidence The document text provides a detailed biography and professional history of an individual named Cédric van Rijckevorsel, listing his qualifications, career progression, and current board memberships, including a role at 'Financière de Tubize SA, a Euronext listed holding company'. This type of biographical disclosure, especially concerning board members or key executives, strongly aligns with documents related to corporate governance, director appointments, or management structure. Given the options, 'Board/Management Information' (MANG) is the most appropriate classification, as it covers announcements of changes or profiles of senior management/directors. It is not a formal financial filing like 10-K or ER, nor is it a general announcement of a report (RPA).
2018-03-23 English
1803 -Bio Kay Davies.pdf
Board/Management Information Classification · 99% confidence The document text provides a detailed biography and professional history of an individual named Kay Davies, highlighting her academic roles, research interests, awards, and board memberships, specifically mentioning her role as a Director of the Biotech Growth Trust and a member of UCB's Governance, Nomination and Compensation Committee (GNCC). This content strongly relates to the composition and background of the company's leadership or board members. This aligns best with the 'Board/Management Information' category, which covers announcements of changes or profiles of senior management and directors.
2018-03-23 English
UCB SA Procuration Assemblée Générale 26 avril 2018 .pdf
Proxy Solicitation & Information Statement Classification · 99% confidence The document is explicitly titled "PROCURATION POUR L'ASSEMBLÉE GÉNÉRALE DES ACTIONNAIRES DU 26 AVRIL 2018" (Proxy for the General Shareholders' Meeting of April 26, 2018). It contains instructions for shareholders on how to appoint a proxy to vote on various resolutions, including the approval of annual accounts, remuneration reports, director re-elections, and long-term incentive plans. This material is designed to solicit shareholder votes and provide necessary information ahead of the meeting, which aligns perfectly with the definition of Proxy Solicitation & Information Statement (PSI). Although it touches upon items typically found in an Annual Report (like approving 2017 accounts), the document's primary function is soliciting proxy votes for the AGM.
2018-03-23 French

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.